アブストラクト
| Title | 自己免疫性肝炎 up to date |
|---|---|
| Subtitle | 今月のテーマ (総説) : 自己免疫性肝・胆道疾患 up to date |
| Authors | 大平弘正, 高橋敦史, 阿部和道1) |
| Authors (kana) | |
| Organization | 1)福島県立医科大学消化器内科学講座 |
| Journal | 日本消化器病学会雑誌 |
| Volume | 121 |
| Number | 1 |
| Page | 10-16 |
| Year/Month | 2024 / 1 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 要旨: 近年, 自己免疫性肝炎(AIH)の有病率は増加しており, 急性肝炎例の割合が約20%を占めている. 日本の診療ガイドラインが2022年1月に改訂され, 診断基準項目の順番の変更, CQを2項目追加, 重症度判定項目の修正, 治療反応性定義の記載, PSCオーバーラップ, 薬物起因性AIH様肝障害, 非侵襲的線維化診断に関する内容が追記となっている. 周辺疾患として, 免疫チェックポイント阻害薬による肝障害や脂肪性肝障害との関連が注目されている. 海外の新たな動向も踏まえながら, わが国としてのAIH診療の対応を確立していく必要がある. |
| Practice | 臨床医学：内科系 |
| Keywords | 診療ガイドライン, 組織学的評価, 免疫チェックポイント阻害薬, 脂肪性肝障害, アザチオプリン |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Tanaka A, Mori M, Matsumoto K, et al : Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepa-titis, and primary sclerosing cholangitis in Japan. Hepatol Res 49 ; 881-889 : 2019
- 2) Takahashi A, Ohira H, Abe K, et al : Increasing incidence of acute autoimmune hepatitis : a na-tionwide survey in Japan. Sci Rep 10 ; 14250 : 2020
- 3) Trivedi PJ, Hirschfield GM : Recent advances in clinical practice : epidemiology of autoimmune liver diseases. Gut 70 ; 1989-2003 : 2021
- 4) de Boer YS, van Gerven NM, Zwiers A, et al : Genome-wide association study identifies vari-ants associated with autoimmune hepatitis type 1. Gastroenterology 147 ; 443-452. e5 : 2014
- 5) Migita K, Jiuchi Y, Furukawa H, et al : Lack of as-sociation between the CARD10 rs6000782 poly-morphism and type 1 autoimmune hepatitis in a Japanese population. BMC Res Notes 8 ; 777 : 2015
残りの30件を表示する
- 6) Longhi MS, Mieli-Vergani G, Vergani D : Regula-tory T cells in autoimmune hepatitis : an updated overview. J Autoimmun 119 ; 102619 : 2021
- 7) Huang Z, Nie S, Wang H, et al : The proportion of regulatory T cells in peripheral blood of patients with autoimmune hepatitis : A systematic review and meta-analysis. Int Immunopharmacol 122 ; 110576 : 2023
- 8) Lin R, Zhou L, Zhang J, et al : Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol 8 ; 5153-5160 : 2015
- 9) Lou J, Jiang Y, Rao B, et al : Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals. Front Cell Infect Micro-biol 10 ; 342 : 2020
- 10) Wei Y, Li Y, Yan L, et al : Alterations of gut mi-crobiome in autoimmune hepatitis. Gut 69 ; 569-577 : 2020
- 11) Abe K, Takahashi A, Fujita M, et al : Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One 13 ; e0198757 : 2018
- 12) 厚生労働科学研究費補助金難治性疾患等政策研究事業「難治性の肝・胆道疾患に関する調査研究」班 : 自己免疫性肝炎(AIH)の診療ガイドライン(2021年), 2022
- 13) Kumagai K, Mawatari S, Moriuchi A, et al : Early-phase prothrombin time-international normalized ratio in acute liver injury indicates the timing of therapeutic intervention and predicts prognostic improvement. Hepatol Res 53 ; 160-171 : 2023
- 14) Pape S, Snijders RJALM, Gevers TJG, et al : Sys-tematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol 76 ; 841-849 : 2022
- 15) Mack CL, Adams D, Assis DN, et al : Diagnosis and management of autoimmune hepatitis in adults and children : 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology 72 ; 671-722 : 2020
- 16) Lohse AW, Sebode M, Bhathal PS, et al : Consen-sus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group : Results of a workshop on AIH histology hosted by the European Reference Net-work on Hepatological Diseases and the Euro-pean Society of Pathology : Results of a workshopon AIH histology hosted by the European Refer-ence Network on Hepatological Diseases and the European Society of Pathology. Liver Int 42 ; 1058-1069 : 2022
- 17) Bunchorntavakul C, Reddy KR : Diagnosis and management of overlap syndromes. Clin Liver Dis 19 ; 81-97 : 2015
- 18) 有永照子 : 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性の肝・胆道疾患に関する調査研究」班令和3年度分担研究報告書, 2022
- 19) Zen Y, Yeh MM : Checkpoint inhibitor-induced liver injury : A novel form of liver disease emerg-ing in the era of cancer immunotherapy. Semin Diagn Pathol 36 ; 434-440 : 2019
- 20) Vollmer O, Felten R, Mertz P, et al : Characteriza-tion of auto-immune hepatitis associated with the use of anti-TNFα agents : An analysis of 389 cases in VigiBase. Autoimmun Rev 19 ; 102460 : 2020
- 21) Takahashi A, Arinaga-Hino T, Ohira H, et al : Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. JGH Open 2 ; 54-58 : 2018
- 22) Takahashi A, Ohira H, Abe K, et al : Increasing incidence of acute autoimmune hepatitis : a na-tionwide survey in Japan. Sci Rep 10 ; 14250 : 2020
- 23) Zachou K, Azariadis K, Lytvyak E, et al : Treat-ment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease. JHEP Rep 5 ; 100778 : 2023
- 24) Mederacke YS, Kirstein MM, Grosshennig A, et al : The PNPLA3 rs738409 GG genotype is associ-ated with poorer prognosis in 239 patients with autoimmune hepatitis. Aliment Pharmacol Ther 51 ; 1160-1168 : 2020
- 25) 三浦 亮, 八木みなみ, 松本康佑, 他 : 既存治療に不耐・不応の自己免疫性肝炎に対するミコフェノール酸モフェチルの使用経験. 日本消化器病学会雑誌 118 ; 318-326 : 2021
- 26) Vergani D, Terziroli Beretta-Piccoli B, Mieli-Vergani G : A reasoned approach to the treat-ment of autoimmune hepatitis. Dig Liver Dis 53 ; 1381-1393 : 2021
- 27) Richardson N, Wootton GE, Bozward AG, et al : Challenges and opportunities in achieving effec-tive regulatory T cell therapy in autoimmune liver disease. Semin Immunopathol 44 ; 461-474 : 2022
- 28) Li J, Zhuang Q, Zhang X, et al : Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients. Can Respir J 2018 ; 9629570 : 2018
- 29) Navarro-Vergara DI, Roldan-Valadez E, Cueto-Robledo G, et al : Portopulmonary Hypertension : Prevalence, Clinical and Hemodynamic Features. Curr Probl Cardiol 46 ; 100747 : 2021
- 30) Kawut SM, Krowka MJ, Trotter JF, et al : Clinical risk factors for portopulmonary hypertension. Hepatology 48 ; 196-203 : 2008
- 31) Atsukawa M, Tsubota A, Hatano M, et al : Preva-lence and characteristics of portopulmonary hy-pertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery cathe-terization. Hepatol Res 50 ; 1244-1254 : 2020
- 32) Marjot T, Buescher G, Sebode M, et al : SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol 74 ; 1335-1343 : 2021
- 33) Efe C, Dhanasekaran R, Lammert C, et al : Out-come of COVID-19 in patients with autoimmune hepatitis : an international multicenter study. He-patology 73 ; 2099-2109 : 2021
- 34) Ghielmetti M, Schaufelberger HD, Mieli-Vergani G, et al : Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination : A novel clinical entity? J Autoimmun 123 ; 102706 : 2021
- 35) Codoni G, Kirchner T, Engel B, et al : Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep 5 ; 100605 : 2022
